Invasive candidiasis is the most common and serious fungal disease worldwide, and the development of antifungal drug resistance in Candida spp. is an emerging problem. Miltefosine, approved as an orphan drug for the therapy of invasive candida infections by the US Food and Drug Administration, has broad-spectrum antifungal activity, but its mechanism of action is unclear. This study evaluated the antifungal drug susceptibility of azole-resistant Candida spp. isolates and found that miltefosine showed good activity, with a geometric mean value of 2 mu g/mL. Miltefosine was found to increase production of intracellular reactive oxygen species (ROS) and induce apoptosis in Candida albicans. RNA sequencing (RNA-Seq) analysis and iTRAQ-labelling-based quantitative proteomic mass spectrometry analysis were undertaken. Aif1 and the oxidative stress pathway involved in miltefosine-mediated apoptosis were identified using global transcriptomic and proteomic combined screening. Miltefosine increased mRNA and protein expressions of Aif1. The localization of Aif1 was examined using confocal microscopy, and the GFP-Aif1 fusion protein was found to be translocated from the mitochondria to the nucleus when sensing miltefosine. Next, the pex8 Delta/Delta strain was constructed, and the minimum inhibitory concentration of miltefosine was found to decrease four-fold (from 2 to 0.5 mu g/mL) and the intracellular ROS increased significantly after knocking out the PEX8 gene. Moreover, miltefosine was found to trigger Hog1 phosphorylation. These findings indicate that Aif1 activation and the Pex8-mediated oxidative stress pathway are the mechanisms of action of miltefosine on C. albicans. The results help to aid understanding of the mechanisms by which miltefosine acts on fungi. (c) 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Cao, YingYing
Wang, Yan
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Wang, Yan
Dai, BaoDi
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Dai, BaoDi
Wang, Bin
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pharm, Shanghai 200438, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Wang, Bin
Zhang, Hai
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pharm, Shanghai 200438, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Zhang, Hai
Zhu, ZhenYu
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Zhu, ZhenYu
Xu, YongGang
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Xu, YongGang
Cao, YongBing
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Cao, YongBing
Jiang, YuanYing
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
Jiang, YuanYing
Zhang, GuoQing
论文数: 0引用数: 0
h-index: 0
机构:
Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pharm, Shanghai 200438, Peoples R ChinaSecond Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China